X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Indoco Remedies with TIMKEN INDIA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

INDOCO REMEDIES vs TIMKEN INDIA - Comparison Results

INDOCO REMEDIES    Change

Indoco Remedies is engaged in the manufacturing and marketing of formulations and active pharmaceutical ingredients (APIs) for domestic as well as the international markets. The company's focus areas include anti-infective, respiratory, anti-diabetic... More

TIMKEN INDIA 
   Change

Tata Timken Ltd. (TTL), the country`s second largest ball-bearing (tapered and cartridge tapered) manufacturer after SKF, has become an 80% subsidiary of the $2.4 billion family controlled Timken USA, after buying out the Tata`s 40% stake in the comp... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    INDOCO REMEDIES TIMKEN INDIA INDOCO REMEDIES/
TIMKEN INDIA
 
P/E (TTM) x 89.4 39.7 225.0% View Chart
P/BV x 3.2 5.6 57.2% View Chart
Dividend Yield % 0.7 0.2 409.1%  

Financials

 INDOCO REMEDIES   TIMKEN INDIA
EQUITY SHARE DATA
    INDOCO REMEDIES
Mar-17
TIMKEN INDIA
Mar-18
INDOCO REMEDIES/
TIMKEN INDIA
5-Yr Chart
Click to enlarge
High Rs3601,008 35.8%   
Low Rs249630 39.5%   
Sales per share (Unadj.) Rs119.0181.5 65.6%  
Earnings per share (Unadj.) Rs8.413.5 61.8%  
Cash flow per share (Unadj.) Rs15.219.9 76.6%  
Dividends per share (Unadj.) Rs1.601.00 160.0%  
Dividend yield (eoy) %0.50.1 430.0%  
Book value per share (Unadj.) Rs70.7103.3 68.5%  
Shares outstanding (eoy) m92.1568.00 135.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.64.5 56.7%   
Avg P/E ratio x36.460.5 60.2%  
P/CF ratio (eoy) x20.041.2 48.5%  
Price / Book Value ratio x4.37.9 54.4%  
Dividend payout %19.17.4 258.8%   
Avg Mkt Cap Rs m28,08355,692 50.4%   
No. of employees `0006.00.8 741.5%   
Total wages/salary Rs m2,167905 239.4%   
Avg. sales/employee Rs Th1,817.015,159.8 12.0%   
Avg. wages/employee Rs Th359.01,111.8 32.3%   
Avg. net profit/employee Rs Th127.71,130.1 11.3%   
INCOME DATA
Net Sales Rs m10,96812,340 88.9%  
Other income Rs m40208 19.0%   
Total revenues Rs m11,00712,549 87.7%   
Gross profit Rs m1,5651,633 95.8%  
Depreciation Rs m633431 146.7%   
Interest Rs m6212 509.0%   
Profit before tax Rs m9091,398 65.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m139478 29.0%   
Profit after tax Rs m771920 83.8%  
Gross profit margin %14.313.2 107.8%  
Effective tax rate %15.334.2 44.6%   
Net profit margin %7.07.5 94.3%  
BALANCE SHEET DATA
Current assets Rs m5,7256,480 88.3%   
Current liabilities Rs m5,4542,489 219.2%   
Net working cap to sales %2.532.3 7.6%  
Current ratio x1.02.6 40.3%  
Inventory Days Days6273 85.7%  
Debtors Days Days7266 108.7%  
Net fixed assets Rs m5,3073,049 174.1%   
Share capital Rs m184680 27.1%   
"Free" reserves Rs m6,3316,343 99.8%   
Net worth Rs m6,5167,023 92.8%   
Long term debt Rs m1,3230-   
Total assets Rs m11,9709,789 122.3%  
Interest coverage x15.6115.5 13.5%   
Debt to equity ratio x0.20-  
Sales to assets ratio x0.91.3 72.7%   
Return on assets %7.09.5 73.1%  
Return on equity %11.813.1 90.3%  
Return on capital %12.420.1 61.7%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m4,5073,467 130.0%   
Fx outflow Rs m1,1413,348 34.1%   
Net fx Rs m3,366119 2,828.2%   
CASH FLOW
From Operations Rs m886390 227.3%  
From Investments Rs m-1,706-638 267.2%  
From Financial Activity Rs m1,316-19 -6,924.7%  
Net Cashflow Rs m497-270 -183.7%  

Share Holding

Indian Promoters % 59.2 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 12.5 5.5 227.3%  
FIIs % 6.0 6.4 93.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.4 13.2 169.7%  
Shareholders   12,805 49,890 25.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare INDOCO REMEDIES With:   TVS SRICHAKRA  TATA INVEST. CORP.  KITEX GARMENTS  INGERSOLL RAND  FINOLEX IND.  



Today's Market

From Urjit Patel to Shaktikanta Das; What Lies Ahead?(Podcast)

The week gone by saw Sensex plunge from 700 points to rise by over 600 points. With a volatile and eventful week, it was a challenge keeping up with the news every day.

Related Views on News

INDOCO REMEDIES Announces Quarterly Results (2QFY19); Net Profit Down 139.4% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, INDOCO REMEDIES has posted a net profit of Rs 78 m (down 139.4% YoY). Sales on the other hand came in at Rs 2 bn (down 17.3% YoY). Read on for a complete analysis of INDOCO REMEDIES's quarterly results.

TIMKEN INDIA Announces Quarterly Results (2QFY19); Net Profit Down 7.2% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, TIMKEN INDIA has posted a net profit of Rs 346 m (down 7.2% YoY). Sales on the other hand came in at Rs 4 bn (up 33.4% YoY). Read on for a complete analysis of TIMKEN INDIA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

It's Almost the Perfect Time to Buy This Safe Stock(The 5 Minute Wrapup)

Dec 6, 2018

My latest StockSelect recommendation ticks all the boxes of a great safe stock.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

Are Foreign Investors Heading Back to the Indian Stock Markets?(Chart Of The Day)

Dec 3, 2018

After months of heavy FII selling, November witnessed a return on foreign money into Indian equities...

DSP Mutual Fund's Sale of DHFL Bonds: Here's What You Need to Know(Outside View)

Dec 5, 2018

PersonalFN explains the probable reason as to why the capital market regulator has initiated DSP Mutual Fund's bond sale that caused DHFL stock to crash.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

INDOCO REMEDIES SHARE PRICE


Dec 14, 2018 (Close)

TRACK INDOCO REMEDIES

  • Track your investment in INDOCO REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON INDOCO REMEDIES

INDOCO REMEDIES - KOTHARI PRODUCTS COMPARISON

COMPARE INDOCO REMEDIES WITH

MARKET STATS